WHO ICTRP trial
A phase Ib study of combination of temsirolimus (Torisel®) and pegylated…
EUCTR2009-010290-21-NL · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2009-010290-21-NL |
|---|---|
| Public title | A phase Ib study of combination of temsirolimus (Torisel®) and pegylated liposomal doxorubicin (PLD, Doxil®/ Caelyx®) in advanced or recurrent breast, endometrial and ovarian cancer |
| Scientific title | A phase Ib study of combination of temsirolimus (Torisel®) and pegylated liposomal doxorubicin (PLD, Doxil®/ Caelyx®) in advanced or recurrent breast, endometrial and ovarian cancer |
| Primary sponsor | University Medical Centre Nijmegen St Radboud |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Netherlands |
| Conditions | advanced or therapy refractory breast cancer, endometrial cancer, or ovarian cancer. |
| Interventions | Trade Name: Torisel Pharmaceutical Form: Concentrate for solution for infusion Trade Name: Caelyx Pharmaceutical Form: Intravenous infusion |
| Registration date | Feb 17, 2009 |
| Secondary IDs | UMCNONCO200902 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: